Article
Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma.
European journal of endocrinology - 1 Sept 2022
Buffet Camille, Allard Lucie, Guillerm Erell, Ghander Cécile, Mathy Elise, Lussey-Lepoutre Charlotte, Julien Nicolas, Touma Eliane, Quilhot Pauline, Godiris-Petit Gaelle, Lacorte Jean-Marc, Leenhardt Laurence, Denis Jérôme Alexandre
Abstract excerpt
Introduction: Recently, targeted therapies using BRAFV600E and MEK inhibitors (dabrafenib and trametinib, respectively) have been recommended in BRAF-mutated anaplastic thyroid carcinoma (ATC). Considering the fast development of ATC, droplet digital PCR (ddPCR) performed on fine-needle aspirate (FNA), which is a rapid, reliable, and low-cost method, appears interesting for the detection of BRAFV600E mutation in...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Humans
- Imidazoles
- Mutation
- Oximes
- Polymerase Chain Reaction
- Proto-Oncogene Proteins B-raf
- Pyridones
- Pyrimidinones
- Thyroid Carcinoma, Anaplastic
- Thyroid Neoplasms